Africa Digital Media Awards

Global site navigation

Local editions

Germany's BioNTech to buy CureVac to boost cancer research
Economy

Germany's BioNTech to buy CureVac to boost cancer research

by  AFP
2 min read
BioNTech hopes its purchase of CureVac will help boost its research into cancer treatments
BioNTech hopes its purchase of CureVac will help boost its research into cancer treatments. Photo: ANDRE PAIN / AFP
Source: AFP

CHECK OUT: Don't let unemployment hold you back. Start your digital marketing journey today.

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.

While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases.

BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases.

"This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin.

PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app!

It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said.

Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof".

BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals.

Both companies are listed on the Nasdaq Composite Index.

They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world.

But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results.

In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Hot: